illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Microport Cardioflow Medtech
Company logo

Microport Cardioflow Medtech | Sustainability Performance

https://en.cardioflowmedtech.com/

Develops and markets medical devices focused on cardiovascular conditions.

2015

China

11 - 50 employees

Medical Device

$25M - 100M in revenue

Not profitable

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6621
Overall
#170
in China
#102
in Medical Device

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

160 out of 174

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
BioKangtai

China, Health Care, Biotechnology


Company logo
Shandong Buchang Pharmaceuticals

China, Health Care, Pharmaceuticals


Company logo
INT Medical Instruments

China, Health Care, Medical Device

Market cap

1.6B $, 2026▼67.7% YoY

Revenue

361.0M $, 2024▼6.9% YoY

R&D intensity

42.38% 2024

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

1.6B $, 2026▼67.7% YoY

Revenue

361.0M $, FY2024▼6.9% YoY

EBITDA

-159.0M $, FY2024▼9.1% YoY

Operating margin

-44% Industry: -147▲137.1% YoY

P/E ratio

-5.7 Industry: 32▼74.7% YoY

Revenue & EBITDA

$361.0MFY2024 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

-270.1M 2024▼12.1% YoY

Capex

158.0M 2024▼81% YoY

Debt/equity ratio

0.0 Industry: 1▼NaN% YoY

R&D intensity

42.4%FY2024

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

-2.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.3

▼ 8.6%

2022

0.3

▼ 5.9%

2023

0.4

▼ 22.0%

2024

1.7

2031

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

27%
Independent Directors

3 out of 11 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


    Available in
    Scale package

    Access
  • Email

  • Email